Guest,您好!  [ 退出系统 ]
 
 
本系统提供的服务仅限于教学、科研及个人学习的目的,请合理使用!
首页 - 文献检索 - 文献细览(期刊文献)
 
PLoS Pathogens
1553-7366 Vol.08, 11(2012)
p.-
Hsp90 Inhibitors Are Efficacious against Kaposi Sarcoma by Enhancing the Degradation of the Essential Viral Gene LANA, of the Viral Co-Receptor EphA2 as well as Other Client Proteins
Wuguo Chen, Sang-Hoon Sin, Kwun Wah Wen, Blossom Damania, Dirk P. Dittmer[*]
Department of Microbiology and Immunology, Program in Global Oncology, Lineberger Comprehensive Cancer Center, Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
 Abstract:Heat-shock protein 90 (Hsp90) inhibitors exhibit activity against human cancers. We evaluated a series of new, oral bioavailable, chemically diverse Hsp90 inhibitors (PU-H71, AUY922, BIIB021, NVP-BEP800) against Kaposi sarcoma (KS). All Hsp90 inhibitors exhibited nanomolar EC50 in culture and AUY922 reduced tumor burden in a xenograft model of KS. KS is associated with KS-associated herpesvirus (KSHV). We identified the viral latency associated nuclear antigen (LANA) as a novel client protein of Hsp90 and demonstrate that the Hsp90 inhibitors diminish the level of LANA through proteasomal degradation. These Hsp90 inhibitors also downregulated EphA2 and ephrin-B2 protein levels. LANA is essential for viral maintenance and EphA2 has recently been shown to facilitate KSHV infection; which in turn feeds latent persistence. Further, both molecules are required for KS tumor formation and both were downregulated in response to Hsp90 inhibitors. This provides a rationale for clinical testing of Hsp90 inhibitors in KSHV-associated cancers and in the eradication of latent KSHV reservoirs.
下载题录  |  原文收割  |  参考译文  |  推荐[0]  |  分享到:
新浪微博 腾讯微博  

关于我们   |   联系我们   |   意见或建议   |   检索技巧   |   在线客服
古扬科技   渝公网备:500199095-00008   渝ICP备:10200524号
建议使用IE6以上版本,1024*768分辨率浏览本页面